We were also able to leverage the subtype predictor together with targeted machine learning to study acquired resistance to quizartinib, a drug used to treat FLT3-ITD (internal tandem duplication) AML patients that is currently undergoing FDA approval.45 This evidence concerns the gene FLT3 and acute myeloid leukemia.